Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPJOHN's "INCYTE"-FUL INVESTMENT IN LIFESEQ GENOMICS DATABASE

Executive Summary

UPJOHN's "INCYTE"-FUL INVESTMENT IN LIFESEQ GENOMICS DATABASE will cost the company $20 mil. under an agreement announced Dec. 1. The Upjohn entrance into gene therapy includes a $10 mil. fee for a non-exclusive subscription to Incyte's human genomics database and access to its high-throughput gene sequencing technology, and $10.1 mil. for a 10% equity stake in the Palo Alto, Calif.-based firm. Upjohn is purchasing 791,000 shares of Incyte common stock at $12.75 per share and will make milestone and royalty payments to Incyte on therapies issuing from their collaboration.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel